Publications by authors named "Ashley H Yuen"
Article Synopsis
- Glucagon-like peptide-1 receptor agonists, like exenatide, offer benefits for type 2 diabetes patients including better blood sugar control, weight loss, and lower cardiovascular risks, leading to a study aimed at finding genetic factors influencing drug effectiveness.
- A pilot study involving 62 healthy volunteers tested exenatide versus saline, revealing that exenatide significantly boosted insulin secretion and glucose clearance but had a minimal effect on insulin sensitivity.
- The findings highlight the importance of specific glucose metabolism measurements and support further research to explore genetic influences on the effectiveness of diabetes medications like semaglutide.
Background: GLP1R agonists provide multiple benefits to patients with type 2 diabetes - including improved glycemic control, weight loss, and decreased risk of major adverse cardiovascular events. Because drug responses vary among individuals, we initiated investigations to identify genetic variants associated with the magnitude of drug responses.
Methods: Exenatide (5 µg, sc) or saline (0.